Prosecution Insights
Last updated: November 20, 2026
Application No. 18/448,526

Treatment for neoplastic diseases

Non-Final OA §102§OTHER
Filed
Aug 11, 2023
Priority
Aug 23, 2010 — provisional 61/376,097 +5 more
Examiner
PAK, MICHAEL D
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Xbiotech Inc.
OA Round
3 (Non-Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
5m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
417 granted / 712 resolved
-1.4% vs TC avg
Strong +30% interview lift
Without
With
+30.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
24 currently pending
Career history
737
Total Applications
across all art units

Statute-Specific Performance

§101
7.9%
-32.1% vs TC avg
§103
22.1%
-17.9% vs TC avg
§102
21.7%
-18.3% vs TC avg
§112
36.5%
-3.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 712 resolved cases

Office Action

§102 §OTHER
Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Claims filed October 16, 2025 is entered. The status of claims 1-9 were not presented and should be presented in the future. Claims 10-11 are pending. Claims 1-9 are previously canceled. Claims 10-11 are examined. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. Claim(s) 10-11 is/are rejected under pre-AIA 35 U.S.C. 102b as being anticipated by Simard (WO 2007/135546). Simard teaches the method of treating human patients with colon tumors administering pharmaceutical composition comprising IgG1 monoclonal antibody against IL-1α and pharmaceutical acceptable vehicle where the metastatic lesions were smaller compared to control without the antibody administration (Figure 1D; page 1, paragraph 3; page 4, paragraph 10-11; page 6, paragraph 18; page 7, paragraph 20; page 8, paragraph 23; page 9, paragraph 24; page 10-page 14, paragraph 34; page 15, paragraph 38, 40; page 20, paragraph 51-52). Simard teaches method treating solid tissue cancer including lung (page 7, para 20). Simard teach a method of treating with mouse anti-human IL-1α antibodies and anti-mouse anti-IL-1α antibody (page 9). Simard teaches the treatment of human cancer (paragraphs 10 and 44-45). Furthermore, the administered antibody had tumoricidal action (15, paragraph 38). The size of the metastatic lesion is greater in control mice than in antibody treated animals (page 14). The administration of the antibody inherently will reduce the size of the cancerous tumor. Simard teach the antibody against human IL-1alpha (paragraphs 35, 40, 42, 44-45). The Simard antibody are the same antibody and inherently have the same Ka, The treatment of cancer will inherently result in the symptoms of cancer severity to be reduced. Applicants argue that Simard reference does not teach the Ka of the anti-human Il-1alpha antibody. However, The same antibody would inherently have the function of the claimed Ka. No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL D PAK whose telephone number is (571)272-0879. The examiner can normally be reached on flexible. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached on 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL D PAK/Primary Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Show 1 earlier event
Jul 16, 2025
Non-Final Rejection mailed — §102, §OTHER
Oct 16, 2025
Response Filed
Jan 28, 2026
Final Rejection mailed — §102, §OTHER
Mar 19, 2026
Response after Non-Final Action
Apr 23, 2026
Notice of Allowance
Jun 11, 2026
Response after Non-Final Action
Jun 29, 2026
Response after Non-Final Action
Nov 18, 2026
Non-Final Rejection mailed — §102, §OTHER (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12791568
TREATMENT AND DIAGNOSIS OF CHRONIC INFLAMMATORY CONDITIONS IN THE LOWER URINARY TRACT
4y 11m to grant Granted Nov 10, 2026
Patent 12773450
CORONAVIRUS VACCINES, COMPOSITIONS, AND METHODS RELATED THERETO
4y 0m to grant Granted Oct 27, 2026
Patent 12760063
ELUATE COLLECTION DURING ANTIBODY CHROMATOGRAPHY
4y 5m to grant Granted Oct 13, 2026
Patent 12714738
METHODS AND AGENTS FOR TREATING ACUTE NEUROINFLAMMATORY INJURY
4y 7m to grant Granted Aug 25, 2026
Patent 12709637
REGULATED SYNTHETIC GENE ACTIVATION SYSTEMS
2y 1m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
89%
With Interview (+30.2%)
3y 9m (~5m remaining)
Median Time to Grant
High
PTA Risk
Based on 712 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month